Valuation: OnKure Therapeutics, Inc.

Market Cap 160M 137M 128M 117M 220M 15.27B 223M 1.51B 589M 7.67B 599M 586M 25.37B P/E 2026 *
-2.15x
P/E 2027 * -2.58x
Enterprise Value 160M 137M 128M 117M 220M 15.27B 223M 1.51B 589M 7.67B 599M 586M 25.37B EV / Sales 2026 *
638x
EV / Sales 2027 * 239x
Free-Float
89.55%
Yield 2026 *
-
Yield 2027 * -
1 day+0.25%
1 week-1.25%
Current month+3.14%
1 month-6.64%
3 months-6.41%
6 months+60.82%
Current year+35.86%
1 week 3.78
Extreme 3.78
4.42
1 month 3.72
Extreme 3.72
4.49
Current year 2.23
Extreme 2.23
5.38
1 year 2.23
Extreme 2.23
5.38
3 years 1.7
Extreme 1.7
20
5 years 1.7
Extreme 1.7
20
10 years 1.7
Extreme 1.7
20
Date Insider Type Main position Quantity % Market Cap.
8/7/26 Free

Director

22,350 0.0553%
8/7/26 Free

Director

22,350 0.0553%
8/7/26 Free

Chairman

22,350 0.0553%
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%-1.25%+39.22% - 160M
-0.49%+4.20%+3.04%+23.60% 51.61B
-1.07%+2.82%+465.96%+570.70% 44.89B
+1.47%+9.79%+35.92%+20.21% 42.77B
+1.44%+7.77%+19.38%+84.65% 42.58B
-0.93%-4.33%+16.18%+55.82% 31.82B
+1.32%+7.30%+33.89%+148.53% 17.33B
-0.60%+1.93% - - 16.63B
+0.47%+4.54%+9.65%+30.73% 14.76B
+1.28%+5.41%+82.40%+46.13% 14.09B
Average +0.31%+3.87%+78.40%+122.55% 27.66B
Weighted average by Cap. +0.21%+4.71%+99.42%+141.47%

Financials

2026 *2027 *
Net sales 250K 214K 200K 183K 344K 23.92M 349K 2.37M 923K 12.02M 939K 918K 39.74M 667K 571K 534K 489K 918K 63.79M 930K 6.31M 2.46M 32.04M 2.5M 2.45M 106M
Net income -64.23M -55.02M -51.48M -47.13M -88.44M -6.15B -89.61M -608M -237M -3.09B -241M -236M -10.21B -70.41M -60.31M -56.43M -51.66M -96.94M -6.74B -98.23M -667M -260M -3.38B -264M -259M -11.19B
Net Debt - -
Logo OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
Employees
45
Date Price Change Volume
26-08-21 US$3.940 +0.25% 59,910
26-08-20 US$3.930 -3.68% 103,519
26-08-19 US$4.080 -3.09% 166,173
26-08-18 US$4.210 +2.43% 108,168
26-08-17 US$4.110 +3.01% 228,695
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.940USD
Average target price
15.50USD
Spread / Average Target
+293.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OKUR Stock